New Drug Development Targeted by Quantum Companies

Quantum computing company Classiq is working with South Korea-based Quantum Intelligence Corp (QIC) on research to accelerate drug development using quantum computing.

The project falls under the Quantum Computing for Life Sciences and Healthcare Center, which Classiq launched with Nvidia last year. The initiative aims to develop and implement quantum algorithms and applications for life sciences and health care.

The new program aims to make drug development more efficient and accurate by integrating Classiq's quantum computing platform with QIC's drug development platform.

The partners plan to use Classiq’s platform to explore how quantum computing could be used for predictive and analytical applications in pharmacology. This includes discovering and designing new drug candidates and the prediction of potential side effects and interactions.

“This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology,” said Classiq CEO Nir Minerbi.

“By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.”

QIC developed a candidate drug testing platform based on quantum computing and AI technologies called QUEST-ADMET. It aims to predict compound properties through electronic charge distribution algorithms to assess potential new drugs for effectiveness and safety.

Related:Nvidia Collaborates for Hybrid Quantum

“Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning itself more as a platform company powered by quantum and AI technology,” said QIC CEO Hwanho Choi.

“Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.”